PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation ...

A new study suggests COPD patients experience improved lung ... in a single once-daily dose in GSK’s Ellipta dry powder inhaler. Novartis says its results support recommendations put forward ...

In June 2014, the US Food and Drug Administration (FDA) approved a new formulation of inhaled insulin (Afrezza- inhalation powder). This is based on particles ... such as asthma or chronic obstructive ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

COPD: Chronic obstructive pulmonary disease; EIB: Exercise-induced bronchoconstriction; IβA: Inhaled β 2-agonist; ICS: Inhaled corticosteroid. Globally, the prevalence of asthma continues to ...

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

It's also important to remember that some inhalers are meant only for people diagnosed with chronic obstructive pulmonary disease (COPD) and don't treat asthma. These medications include: In many ...

A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers. Developed by Australian medtech firm ...